Beta

Atrium therapeutics, inc.RNA.US Overview

US StockHealthcare
(No presentation for RNA)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

RNA AI Insights

RNA Overall Performance

RNA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RNA Recent Performance

-2.71%

Atrium therapeutics, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

RNA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check RNA's Trend

RNA Key Information

RNA Valuation Metrics

RNA Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Price of RNA

RNA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RNA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-30.72
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
11.24
PB Ratio
1.01
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-2541.68%
Revenue Growth (YoY)
72.10%
Profit Growth (YoY)
72.10%
3-Year Revenue Growth
-32.30%
3-Year Profit Growth
-32.30%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-30.72
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
11.24
PB Ratio
1.01
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-2541.68%
Revenue Growth (YoY)
72.10%
Profit Growth (YoY)
72.10%
3-Year Revenue Growth
-32.30%
3-Year Profit Growth
-32.30%

  • When is RNA's latest earnings report released?

    The most recent financial report for Atrium therapeutics, inc. (RNA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RNA's short-term business performance and financial health. For the latest updates on RNA's earnings releases, visit this page regularly.

  • What is the operating profit of RNA?

    According to the latest financial report, Atrium therapeutics, inc. (RNA) reported an Operating Profit of -29.09M with an Operating Margin of -3,386.5% this period, representing a growth of 75.96% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is RNA's revenue growth?

    In the latest financial report, Atrium therapeutics, inc. (RNA) announced revenue of 859K, with a Year-Over-Year growth rate of -71.11%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • Does RNA go with three margins increasing?

    In the latest report, Atrium therapeutics, inc. (RNA) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -3,386.5%%, and net margin of -3,391.9%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess RNA's profit trajectory and future growth potential.

  • Is RNA's EPS continuing to grow?

    According to the past four quarterly reports, Atrium therapeutics, inc. (RNA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RNA?

    Atrium therapeutics, inc. (RNA)'s Free Cash Flow (FCF) for the period is -20.13M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 80.6% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.